A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ESTEEM-2
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Nov 2017 Results of pooled analysis (n=2242) assessing MACE, malignancies, and serious infections incidences in subjects from ESTEEM 1 and 2 (plaque psoriasis) and PALACE 1-3 (psoriatic arthritis) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jun 2017 Results of pooled analysis from Esteem and Palace 1-3 Phase 3 Trials presented at the 18th Annual Congress of the European League Against Rheumatism
    • 14 Apr 2017 Results of a pooled safety analysis of apremilast in patients from two randomized trials (ESTEEM-1 and ESTEEM-2; n=1184), published in the Journal of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top